Why GW Pharmaceuticals (GWPH) Stock Is Up Today

NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH) shares are up 3% to $64 on Monday following the announcement that its Sativex drug treatment had received a "fast track" designation from regulators at the Food and Drug Administration.

The fast track program is designed to facilitate the development of drugs intended to treat life threatening diseases. 

Sativex, a cannaboid based treatments that is comprised of CBD (cannabidiol) and THC, is designed to treat pain associated with advanced stages of cancer. It is currently in Phase 3 clinical trials.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. 

GWPH Chart

GWPH data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months.Learn more.

If you liked this article you might like

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

Here Is the Buzz on My Under-the-Radar Top ETF Pick for 2018

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

California Cannabis Growers Celebrate New Year's Day as Weed Goes Legal

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

President Trump Looks Set for a Major Victory on Tax Reform: Market Recon

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)

Hold on for a Wild Ride: Cramer's 'Mad Money' Recap (Friday 12/1/17)